TAKAYASU ARTERİTİNDE TEK MERKEZ DENEYİMİ

Year 2020, Volume: 10 Issue: 4, 596 - 599, 30.12.2020

Muhammet Limon , Dilek Tezcan Semral Gülcemal , Sema Yılmaz

https://doi.org/10.16899/jcm.648730

Abstract

Giriş-Amaç: Takayasu arteriti(TA), etyolojisi tam olarak bilinmeyen aorta ve ana
dalları olmak üzere büyük damarları etkileyen kronik granülomatöz büyük damar
vaskülitidir. Bu çalışma ile kliniğimizde takip edilen TA sıklığı ve tedavi cevapları
değerlendirilmiştir.

Gereç-Yöntem: Bu çalışma retrospektif olarak Ocak
2016-Ekim 2019 arasında Romatoloji Bilim Dalında yapıldı. Çalışmaya 18 yaş
üzeri 1990 Amerika Romatoloji Cemiyeti Kriterlerine göre TA tanısı konulan 20
hasta dahil edildi.

Bulgular: Kliniğimizde retrospektif
olarak değerlendirilen 20 tane TA hastasının 17 tanesi kadın, 3 tanesi
erkekti.  Hastaların yaş ortalaması 38,2
olarak bulundu. TA’lı hastaların ortalama sedimantasyon: 34 mm/s, CRP: 16 mg/L
olarak bulundu. RF ve ANCA bütün hastalarda negatif bulundu. TA’ya bağlı
vasküler tutulum değerlendirildiğinde %90 sıklıkta subklavian arter, %50
karotis arter, %40 abdominal aorta, %35 torasik aorta, %15 renal arter tutulumu
gözlendi. Medikal tedavide %100 kortikosteroid, %55 siklofosfamid, %45 metotreksat,
%25 azatioprin, %5 leflunomid, %5 tosilizumab kullanıldığı gözlendi. Geleneksel
tedavi (metotreksat, azatioprin, leflunomid) ile %45 hastanın remisyonda
olduğu, %10 hastanın dirençli olması nedeniyle siklofosfamid verildiği görüldü.
Hastaların %45’inde yaygın damar tutuluşu nedeniyle siklofosfamid ve kortikosteroid
kombinasyonu ilk tedavi olarak tercih edildiği görüldü. Siklofosfamid tedavisi
alan hastaların idamesinde sırayla %25 
infliksimab,%15 metotreksat,%10 azatioprin, %5  metotreksat ve azatioprin verilmiştir.

Tartışma-Sonuç: Bu çalışmada TA’lı
hastaların demografik, klinik, anjiografik bulguları
ve medikal tedavi yanıtları değerlendirilmiştir. TA’nın demografik, klinik ve
anjiografi bulguları literatür ile uyumlu bulunmuştur. TA’nın medikal
tedavisinde kortikosteroidler ve metotreksat, azatioprin, leflunomid gibi geleneksel
tedaviler verilir. Geleneksel tedavilere dirençli olgularda anti-TNF, IL-6
blokeri verildiği gözlenmiştir.

Keywords

Takayasu arteriti, sıklık

References

• 1. Lupi-Herrera E, Sanchez-Torres G, Marcushamer J, Mispireta J, Horwitz S, Vela JE. Takayasu's arteritis. Clinical study of 107 cases. American heart journal. 1977;93(1):94-103.
• 2. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis & Rheumatism. 1990;33(8):1129-34.
• 3. Dabague J, Reyes PA. Takayasu arteritis in Mexico: a 38-year clinical perspective through literature review. International journal of cardiology. 1996;54:S87-S93.
• 4. Seko Y, Minota S, Kawasaki A, Shinkai Y, Maeda K, Yagita H, et al. Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu's arteritis. The Journal of clinical investigation. 1994;93(2):750-8.
• 5. Park MC, Lee SW, Park YB, Chung N, Lee SK. Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scandinavian journal of rheumatology. 2005;34(4):284-92.
• 6. Sharma B, Jain S, Sagar S. Systemic manifestations of Takayasu arteritis: the expanding spectrum. International journal of cardiology. 1996;54:S121-S6.
• 7. Kerr G. Takayasu's arteritis, Rheum Dis in the acute stage of TA. Arthritis Rheuma-N Amer. 1995;211(4):1041-3.
• 8. Jain S, Kumari S, Ganguly N, Sharma B. Current status of Takayasu arteritis in India. International Journal of Cardiology. 1996;54:S95-S100.
• 9. Nakabayashi K, Kurata N, Nangi N, Miyake H, Nagasawa T. Pulmonary artery involvement as first manifestation in three cases of Takayasu arteritis. International journal of cardiology. 1996;54:S147-S53.
• 10. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Annals of internal medicine. 1994;120(11):919-29.
• 11. Michel B, Arend W, Hunder G. Clinical differentiation between giant cell (temporal) arteritis and Takayasu's arteritis. The Journal of rheumatology. 1996;23(1):106-11.
• 12. Neidhart B, Kosek R, Bachmann LM, Stey C. Exertional dyspnea as initial manifestation of Takayasu's arteritis–A case report and literature review. BMC pulmonary medicine. 2001;1(1):3.
• 13. Koyabu S, Isaka N, Yada T, Konishi T, Nakano T. Severe respiratory failure caused by recurrent pulmonary hemorrhage in Takayasu's arteritis. Chest. 1993;104(6):1905-6.
• 14. Mason JC. Takayasu arteritis—advances in diagnosis and management. Nature reviews rheumatology. 2010;6(7):406.
• 15. Sharma B, Sagar S, Singh AP, Suri S. Takayasu arteritis in India. Heart and Vessels. 1992;7(1):37-43.
• 16. Ishikawa K, Maetani S. Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. Circulation. 1994;90(4):1855-60.
• 17. Alibaz-Oner F, Yilmaz N, Can M, Direskeneli H. A case of Takayasu's arteritis associated with familial Mediterranean fever. Clinical and experimental rheumatology. 2012;30(3 Suppl 72):S117.
• 18. Zihni FY, Kalfa M, Ocakçı PT, Tarhan F, Parildar M, Keser G, et al. Coexistence of Takayasu’s arteritis with familial Mediterranean fever. Rheumatology international. 2012;32(6):1675-8.
• 19. Bicakcigil M, Aksu K, Kamali S, Ozbalkan Z, Ates A, Karadag O, et al. Takayasu's arteritis in Turkey—clinical and angiographic features of 248 patients. Clinical & Experimental Rheumatology. 2009;27(1):S59.
• 20. Tso E, Flamm SD, White RD, Schvartzman PR, Mascha E, Hoffman GS. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2002;46(6):1634-42.
• 21. Arnaud L, Haroche J, Malek Z, Archambaud F, Gambotti L, Grimon G, et al. Is 18F‐fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2009;60(4):1193-200.
• 22. Lee KH, Cho A, Choi YJ, Lee SW, Ha YJ, Jung SJ, et al. The role of 18F‐fluorodeoxyglucose–positron emission tomography in the assessment of disease activity in patients with Takayasu arteritis. Arthritis & Rheumatism. 2012;64(3):866-75.
• 23. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid‐resistant or relapsing Takayasu arteritis with methotrexate. Arthritis & Rheumatism. 1994;37(4):578-82.
• 24. Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. The Journal of rheumatology. 2003;30(8):1793-8.
• 25. Edwards K, Lindsley H, Lai C, Van PV. Takayasu arteritis presenting as retinal and vertebrobasilar ischemia. The Journal of rheumatology. 1989;16(7):1000-2.
• 26. Cash J, Engelbrecht J. Takayasu's arteritis in western South Dakota. South Dakota journal of medicine. 1990;43(9):5-9.
• 27. Rodríguez-Hurtado F, Sabio J, Lucena J, Jiménez-Alonso J. Ocular involvement in Takayasu's arteritis: response to cyclophosphamide therapy. European journal of medical research. 2002;7(3):128-30.
• 28. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti–tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2004;50(7):2296-304.
• 29. Comarmond C, Plaisier E, Dahan K, Mirault T, Emmerich J, Amoura Z, et al. Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmunity reviews. 2012;11(9):678-84.
• 30. Nishimoto N, Nakahara H, Yoshio‐Hoshino N, Mima T. Successful treatment of a patient with takayasu arteritis using a humanized anti–interleukin‐6 receptor antibody. Arthritis & rheumatism. 2008;58(4):1197-200.
• 31. Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology. 2011;51(1):151-6.